oncnursingnews1h
Aspirin Linked to Lower CRC Recurrence in Patients With PI3K Mutations
Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...
oncnursingnews21h
22% of Community Providers Reported Biomarker Testing in Gastric/GEJ Cancers
Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...
oncnursingnews21h
FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...
oncnursingnews23h
Tislelizumab Plus Chemotherapy Demonstrates Strong Anti-Tumor Activity in ESCC
The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...
oncnursingnews1d
Nivolumab/Chemo Shows Lasting Benefit in Advanced Gastroesophageal Cancers
Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.
oncnursingnews1d
Long-Term Survival Benefit Seen With Nivolumab Plus Chemo in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer
Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.
oncnursingnews5d
Ann Culkin, RN, OCN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews5d
Katie Goodman, RN, BSN, CCRP
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews6d
Cancer Prevention Foundation
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews6d
Dorothy N. Pierce
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews7d
Donna L. Berry, PhD, RN, AOCN, FAAN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews8d
Adding Lenvatinib/Pembrolizumab to TACE Extends PFS in Unresectable Liver Cancer
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to confirm this finding. A combination of transarterial chemoembolization ...